Chart pattern: Triple Bottom (weekly)
▲ Broken out
Broke on Oct 16, 2026 · measured target $33.92 (+15%). Details →
Nov 3, 4:19 PM ET
Pfizer's board unanimously elected Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026, after she served as interim CFO since August 16, 2026. The filing sets her base salary at $1,300,000 and her target annual cash incentive at $1,300,000, and it does not report any financial results or change to guidance.
- Cecile Guegan appointed CFO and Executive Vice President, effective November 1, 2026; interim CFO since August 16, 2026
- Annual base salary of $1,300,000
- Annual target cash incentive of $1,300,000, equal to 100% of base salary
- She will oversee all corporate finance functions, including audit, treasury, investor relations and tax
Read the filing on SEC.gov ↗
Nov 3, 8:07 AM ET
Pfizer announced third-quarter 2026 revenues of $16.6 billion, matching the prior-year period operationally, while reporting adjusted diluted EPS of $0.87. Driven by solid performance in non-COVID and newly launched products, the company raised its full-year 2026 revenue guidance to a range of $62.0 to $64.0 billion and narrowed its adjusted diluted EPS guidance to $2.95 to $3.05. Shareholders also saw the appointment of Cecile Guegan as Chief Financial Officer and Executive Vice President.
- Third-quarter 2026 revenues reached $16.6 billion, with non-COVID products growing 7% operationally.
- Full-year 2026 revenue guidance was raised by $1.5 billion at the midpoint to $62.0 to $64.0 billion.
- Adjusted diluted EPS guidance for full-year 2026 was raised and narrowed to $2.95 to $3.05.
- Cecile Guegan was appointed Chief Financial Officer and Executive Vice President effective November 1, 2026.
Read the filing on SEC.gov ↗
Aug 4, 7:02 AM ET
Pfizer reported second-quarter 2026 revenue of $15.0 billion, up 3% from a year earlier, and a reported loss of $0.04 per share, which reflects $4.3 billion in non-cash intangible asset impairments. Adjusted diluted EPS was $0.77, compared with $0.78 a year earlier. Pfizer raised its full-year 2026 revenue guidance midpoint by $500 million to a range of $60.5 to $62.5 billion and reaffirmed adjusted EPS guidance of $2.80 to $3.00, which absorbs an expected impact of about $0.10 from the Innovent Biologics transaction.
- Q2 2026 revenue was $15.0 billion, up 3% reported and 1% operationally; reported loss per share was $(0.04) versus EPS of $0.51 a year earlier.
- Full-year 2026 revenue guidance raised to $60.5 to $62.5 billion; adjusted diluted EPS guidance reaffirmed at $2.80 to $3.00.
- Pfizer announced $2.5 billion of additional anticipated productivity savings, expected to be realized from 2027 through 2029.
- Pfizer is not planning share repurchases in 2026; $3.3 billion remains under its existing authorization.
Read the filing on SEC.gov ↗
Jun 18, 1:17 PM ET
Pfizer said on June 18, 2026 that it is reaffirming all components of its full-year 2026 guidance, following its announcement of a Chief Financial Officer transition the same day. The guidance includes revenues of $59.5 billion to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00, unchanged from the December 16, 2025 guidance and the May 5, 2026 reaffirmation.
- Full-year 2026 revenue guidance reaffirmed at $59.5 billion to $62.5 billion
- Adjusted diluted EPS guidance reaffirmed at $2.80 to $3.00
- Guidance first issued December 16, 2025 and reaffirmed May 5, 2026 on the first quarter earnings call
- Filing follows a Chief Financial Officer transition announcement made June 18, 2026
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.